Avidity Biosciences, Inc.

Avidity Biosciences, Inc. is a biotechnology company founded in 2013 in the United States. The company focuses on developing a new class of oligonucleotide-based therapies aimed at revolutionizing RNA therapeutics. Avidity is committed to profoundly improving people’s lives by targeting the underlying genetic drivers of diseases. To achieve this, the company leverages its proprietary AOC platform, which enables the design, engineering, and development of therapeutics with the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide-based therapies. This innovative approach allows Avidity to redefine RNA therapeutics and deliver breakthrough therapies to patients. The company has recently received a significant $461.00MPost-IPO Equity investment on 13 June 2024. Avidity's initiative to invest in its platform, pipeline, and people demonstrates its dedication to advancing its science and overall mission. As Avidity progresses, it aims to share its ideas and company progress while delivering on its vision to bring transformative therapies to patients.